Quotient Limited (QTNT) Reaches $4.09 After 4.00% Up Move; WOLTERS KLUWER NV (WOLTF) Shorts Decreased By 13.39%

February 15, 2018 - By Hazel Jackson

WOLTERS KLUWER NV (OTCMKTS:WOLTF) had a decrease of 13.39% in short interest. WOLTF’s SI was 51,100 shares in February as released by FINRA. Its down 13.39% from 59,000 shares previously. It closed at $53.125 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Quotient Limited (NASDAQ:QTNT) is a huge mover today! The stock increased 4.07% or $0.16 during the last trading session, reaching $4.09. About 114,084 shares traded. Quotient Limited (NASDAQ:QTNT) has declined 16.87% since February 15, 2017 and is downtrending. It has underperformed by 33.57% the S&P500.The move comes after 6 months positive chart setup for the $186.46 million company. It was reported on Feb, 15 by Barchart.com. We have $4.25 PT which if reached, will make NASDAQ:QTNT worth $7.46 million more.

Wolters Kluwer N.V., together with its subsidiaries, provides information, software, and services in Europe, North America, the Asia Pacific, and internationally. The company has market cap of $13.10 billion. The firm operates in four divisions: Health; Tax & Accounting; Governance, Risk & Compliance; and Legal & Regulatory. It has a 22.68 P/E ratio. The Health segment provides solutions in the areas of clinical decision support, clinical drug information, clinical documentation, clinical terminologies, clinical surveillance, nursing education and practice, medical research, and continuing education services; and medical, nursing, and allied health journal and book publishing solutions to healthcare professionals, medical librarians, and corporate researchers.

Investors sentiment decreased to 1.42 in 2017 Q3. Its down 6.98, from 8.4 in 2017Q2. It fall, as 7 investors sold Quotient Limited shares while 12 reduced holdings. 9 funds opened positions while 18 raised stakes. 21.37 million shares or 49.89% less from 42.64 million shares in 2017Q2 were reported. Morgan Stanley has invested 0% of its portfolio in Quotient Limited (NASDAQ:QTNT). Tiaa Cref Investment Mngmt Limited Co has invested 0% in Quotient Limited (NASDAQ:QTNT). 36,016 are held by Deutsche Bancorp Ag. Jpmorgan Chase & Commerce holds 0% of its portfolio in Quotient Limited (NASDAQ:QTNT) for 16,425 shares. Polar Cap Ltd Liability Partnership reported 0.19% stake. Cormorant Asset Mgmt Ltd Liability reported 3.49M shares. Meeder Asset Management Incorporated owns 167 shares. Sio Capital Mngmt Limited Liability Company owns 2.34 million shares or 6% of their US portfolio. The New York-based Bnp Paribas Arbitrage has invested 0% in Quotient Limited (NASDAQ:QTNT). Perceptive Advsrs Ltd Liability Co holds 0.7% or 3.73 million shares. Voya Management Lc invested in 12,325 shares. Ameriprise Fincl has invested 0% in Quotient Limited (NASDAQ:QTNT). Wells Fargo Mn invested 0% in Quotient Limited (NASDAQ:QTNT). State Street Corporation reported 0% of its portfolio in Quotient Limited (NASDAQ:QTNT). Northern invested in 0% or 241,860 shares.

Since August 15, 2017, it had 0 insider buys, and 2 selling transactions for $904,595 activity. The insider COWAN D J PAUL E sold 45,540 shares worth $160,296.

Among 3 analysts covering Quotient (NASDAQ:QTNT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quotient has $30 highest and $12.0 lowest target. $17.25’s average target is 321.76% above currents $4.09 stock price. Quotient had 6 analyst reports since August 11, 2015 according to SRatingsIntel. On Wednesday, November 4 the stock rating was maintained by UBS with “Buy”. The firm has “Buy” rating given on Tuesday, February 6 by BTIG Research. The firm has “Buy” rating by Jefferies given on Tuesday, August 11. As per Wednesday, November 1, the company rating was maintained by Jefferies. The company was upgraded on Friday, August 14 by Zacks. The firm earned “Buy” rating on Thursday, August 31 by BTIG Research.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: